公开(公告)号：US20180086829A1

公开(公告)日：2018-03-29

申请号：US15696972

申请日：2017-09-06

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Chengcheng ZHANG ,  Mi DENG ,  Wei XIONG ,  Zhiqiang AN ,  Ningyan ZHANG ,  Xun GUI ,  Junke ZHENG

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/02 ,  A61K45/06 ,  A61K39/395 ,  G01N33/574

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61P35/02 ,  C07K16/3061 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/531 ,  G01N33/57426 ,  G01N33/57492 ,  G01N2333/70503

Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.

公开(公告)号：US20200079851A1

公开(公告)日：2020-03-12

申请号：US16678049

申请日：2019-11-08

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Chengcheng ZHANG ,  Mi DENG ,  Wei XIONG ,  Zhiqiang AN ,  Ningyan ZHANG ,  Xun GUI ,  Junke ZHENG

IPC: C07K16/28 ,  G01N33/574 ,  C07K16/30 ,  A61K45/06 ,  A61K39/395 ,  A61P35/02 ,  C12N15/113

Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.

公开(公告)号：US20180177847A1

公开(公告)日：2018-06-28

申请号：US15834004

申请日：2017-12-06

Applicant: The Board of Regents of the University of Texas System ,  Icahn School of Medicine at Mount Sinai

Inventor： Shu-Hsia CHEN ,  Chengcheng ZHANG ,  Xunlei KANG ,  Junke ZHENG ,  Masato UMIKAWA

IPC: A61K38/18 ,  G01N33/68 ,  A61K31/713 ,  A61K35/15 ,  A61K38/07 ,  A61K38/16 ,  A61K39/395 ,  A61K45/06 ,  A61K31/7105 ,  C07K16/28

CPC classification number: A61K38/1891 ,  A61K31/7105 ,  A61K31/713 ,  A61K35/15 ,  A61K38/07 ,  A61K38/16 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/2803 ,  G01N33/6872 ,  G01N2333/515 ,  G01N2333/70503 ,  G01N2500/04 ,  G01N2800/24 ,  G01N2800/245 ,  G01N2800/7028 ,  G01N2800/7095 ,  A61K2300/00

Abstract: Provided herein are compositions and methods useful for increasing a pro-inflammatory immune response, treating an autoimmune disorder, inflammation, or transplant rejection in a mammal by activating a leukocyte immunoglobulin-like receptor (LILR) protein. Also provided are compositions and methods useful for increasing a pro-inflammatory immune response, treating cancer, and treating infectious disease in a mammal by blocking the activation of a LILR protein.

公开(公告)号：US20170304240A1

公开(公告)日：2017-10-26

申请号：US15312790

申请日：2015-05-12

Applicant: The Board of Regents of the University of texas System

Inventor： Chengcheng ZHANG ,  Yi LIU ,  Junke ZHENG ,  Mi DENG ,  Chuo CHEN ,  Jiawei LIU

IPC: A61K31/194 ,  C12N5/078 ,  A61K31/155 ,  A61K31/20 ,  A61K31/197 ,  C12N5/0789 ,  A61K45/06 ,  C07C279/14

CPC classification number: A61K31/194 ,  A61K31/155 ,  A61K31/197 ,  A61K31/20 ,  A61K45/06 ,  C07C279/14 ,  C12N5/0634 ,  C12N5/0647

Abstract: The present disclosure relates to methods of using a compound to induce regeneration of hematopoietic stem cells or increase the recovery of red blood cells. In some aspects, the present methods can be used to with or in place of erythropoietin in patients to mitigate the side effects of erythropoietin.